Langren Carl W. 4

Accession 0001126234-19-000102

CIK 0001126234other

View on SEC.gov Company Profile

Filed

Aug 1, 8:00 PM ET

Accepted

Aug 2, 6:38 PM ET

Size

59.1 KB

Accession

0001126234-19-000102

Insider Transaction Report

Form 4

Period: 2019-07-31

NEWLINK GENETICS CORP(NLNK)

Langren Carl W.

Principal Accounting Officer

Transactions

Award
Stock Option (Right to Buy)
2019-07-31+1,190→ 1,190 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (1,190 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+589→ 589 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (589 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+1,639→ 1,639 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (1,639 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−20,000→ 0 total
Exercise: $10.78Exp: 2026-08-08→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+278→ 278 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (278 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−2,380→ 0 total
Exercise: $3.07From: 2011-03-03Exp: 2020-03-02→ Common Stock (2,380 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−16,300→ 0 total
Exercise: $43.65Exp: 2025-01-01→ Common Stock (16,300 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−23,809→ 0 total
Exercise: $7.00From: 2012-10-19Exp: 2021-10-18→ Common Stock (23,809 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−8,989→ 0 total
Exercise: $34.73Exp: 2026-01-03→ Common Stock (8,989 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+281→ 281 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (281 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+9,392→ 9,392 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (9,392 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+330→ 330 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (330 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+8,333→ 8,333 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (8,333 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+9,038→ 9,038 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (9,038 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−15,000→ 0 total
Exercise: $6.87From: 2013-01-19Exp: 2022-01-18→ Common Stock (15,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+5,472→ 5,472 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (5,472 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,028→ 2,028 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,028 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+6,692→ 6,692 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (6,692 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,309→ 2,309 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,309 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+3,487→ 3,487 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (3,487 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−16,666→ 0 total
Exercise: $7.00From: 2012-04-14Exp: 2021-04-13→ Common Stock (16,666 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,867→ 2,867 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,867 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−20,000→ 0 total
Exercise: $11.79From: 2014-01-14Exp: 2023-01-13→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+3,539→ 3,539 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (3,539 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+3,129→ 3,129 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (3,129 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−27,000→ 0 total
Exercise: $21.38Exp: 2024-01-01→ Common Stock (27,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+328→ 328 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (328 underlying)

Footnotes (7)

[F1]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F2]The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
[F3]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every three cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F4]The option provided that it would vest in 48 equal monthly installments beginning the first month after grant date subject to the Reporting Person's continuous service as of such date.
[F5]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every four cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F6]The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date.
[F7]The option provided that it would vest and in 36 equal monthly installments beginning on September 9, 2016, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Documents

1 file

4
wf-form4_156478549625602.xmlPrimary
FORM 4

Issuer

NEWLINK GENETICS CORP

CIK 0001126234

→

Entity typeother

Related Parties

filerCIK 0001591245

Filing Metadata

Form type: 4
Filed: Aug 1, 8:00 PM ET
Accepted: Aug 2, 6:38 PM ET
Size: 59.1 KB

View on SEC.gov